Ontology highlight
ABSTRACT:
PROVIDER: EGAD00010001703 | EGA |
REPOSITORIES: EGA
Fraser Michael M Sabelnykova Veronica Y VY Yamaguchi Takafumi N TN Heisler Lawrence E LE Livingstone Julie J Huang Vincent V Shiah Yu-Jia YJ Yousif Fouad F Lin Xihui X Masella Andre P AP Fox Natalie S NS Xie Michael M Prokopec Stephenie D SD Berlin Alejandro A Lalonde Emilie E Ahmed Musaddeque M Trudel Dominique D Luo Xuemei X Beck Timothy A TA Meng Alice A Zhang Junyan J D'Costa Alister A Denroche Robert E RE Kong Haiying H Espiritu Shadrielle Melijah G SM Chua Melvin L K ML Wong Ada A Chong Taryne T Sam Michelle M Johns Jeremy J Timms Lee L Buchner Nicholas B NB Orain Michèle M Picard Valérie V Hovington Helène H Murison Alexander A Kron Ken K Harding Nicholas J NJ P'ng Christine C Houlahan Kathleen E KE Chu Kenneth C KC Lo Bryan B Nguyen Francis F Li Constance H CH Sun Ren X RX de Borja Richard R Cooper Christopher I CI Hopkins Julia F JF Govind Shaylan K SK Fung Clement C Waggott Daryl D Green Jeffrey J Haider Syed S Chan-Seng-Yue Michelle A MA Jung Esther E Wang Zhiyuan Z Bergeron Alain A Dal Pra Alan A Lacombe Louis L Collins Colin C CC Sahinalp Cenk C Lupien Mathieu M Fleshner Neil E NE He Housheng H HH Fradet Yves Y Tetu Bernard B van der Kwast Theodorus T McPherson John D JD Bristow Robert G RG Boutros Paul C PC
Nature 20170109 7637
Prostate tumours are highly variable in their response to therapies, but clinically available prognostic factors can explain only a fraction of this heterogeneity. Here we analysed 200 whole-genome sequences and 277 additional whole-exome sequences from localized, non-indolent prostate tumours with similar clinical risk profiles, and carried out RNA and methylation analyses in a subset. These tumours had a paucity of clinically actionable single nucleotide variants, unlike those seen in metastat ...[more]